News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

C.R. Bard Closes Federal Cancer Treatment Beef for $51 Million



5/14/2013 9:04:10 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

C.R. Bard closes the deal it made last year with federal authorities to settle a probe into its brachytherapy cancer treatment business in return for a $51 million payment. C.R. Bard (NYSE:BCR) said it closed a deal reached last year with federal prosecutors to settle a probe into its brachytherapy business with a $51 million payment. The U.S. Health & Human Services Dept. subpoenaed Murray Hills, N.J.-based Bard in November 2006 over the cancer treatment business, under the False Claims Act and federal healthcare fraud statutes, according to regulatory filings.

Help employers find you! Check out all the jobs and post your resume.

Read at MassDevice


comments powered by Disqus
C.R. Bard
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES